Published in Med Res Rev on June 23, 2010
Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development. Proc Natl Acad Sci U S A (2016) 1.42
The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis. Front Oncol (2014) 1.33
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
Hrr25/CK1δ-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth. J Cell Biol (2015) 0.91
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci (2012) 0.89
The casein kinase 2-nrf1 axis controls the clearance of ubiquitinated proteins by regulating proteasome gene expression. Mol Cell Biol (2013) 0.86
Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder. J Acquir Immune Defic Syndr (2014) 0.85
Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2. J Proteome Res (2011) 0.85
Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors. Mol Pain (2014) 0.82
Transcriptome analysis of HIV-infected peripheral blood monocytes: gene transcripts and networks associated with neurocognitive functioning. J Neuroimmunol (2013) 0.82
Bioactive marine drugs and marine biomaterials for brain diseases. Mar Drugs (2014) 0.81
Circadian gene variants in cancer. Ann Med (2014) 0.81
Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants. Pharmacogenomics (2014) 0.81
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem (2014) 0.80
2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε. Amino Acids (2012) 0.79
Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One (2012) 0.79
The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation. Biomed Res Int (2015) 0.78
CK2-An Emerging Target for Neurological and Psychiatric Disorders. Pharmaceuticals (Basel) (2017) 0.78
Crosstalk between casein kinase II and Ste20-related kinase Nak1. Cell Cycle (2013) 0.78
Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. J Neuroinflammation (2016) 0.78
The New Role for an Old Kinase: Protein Kinase CK2 Regulates Metal Ion Transport. Pharmaceuticals (Basel) (2016) 0.78
FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration. Cell Death Differ (2016) 0.77
SNP-PRAGE: SNP-based parametric robust analysis of gene set enrichment. BMC Syst Biol (2011) 0.77
Interaction of CK1δ with γTuSC ensures proper microtubule assembly and spindle positioning. Mol Biol Cell (2015) 0.77
Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol Pharmacol (2012) 0.76
Structure of the kinase domain of Gilgamesh from Drosophila melanogaster. Acta Crystallogr F Struct Biol Commun (2014) 0.75
Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol Neurodegener (2016) 0.75
Novel group-based QSAR and combinatorial design of CK-1δ inhibitors as neuroprotective agents. BMC Bioinformatics (2016) 0.75
CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application. Front Cell Dev Biol (2015) 0.75
Organic azides: an exploding diversity of a unique class of compounds. Angew Chem Int Ed Engl (2005) 3.62
Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives. Bioorg Med Chem (2007) 1.98
Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines. J Am Soc Echocardiogr (2007) 1.64
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS (2009) 1.35
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr (2005) 1.33
Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J Nat Prod (2006) 1.25
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev (2005) 1.21
Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.08
The recent impact of solid-phase synthesis on medicinally relevant benzoannelated nitrogen heterocycles. Bioorg Med Chem (2002) 1.03
NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci (2007) 1.00
Bap, a biofilm matrix protein of Staphylococcus aureus prevents cellular internalization through binding to GP96 host receptor. PLoS Pathog (2012) 1.00
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des (2006) 0.99
Relative contributions of lipooligosaccharide inner and outer core modifications to nontypeable Haemophilus influenzae pathogenesis. Infect Immun (2013) 0.96
Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci (2012) 0.96
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep (2007) 0.96
Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorg Med Chem (2008) 0.94
Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. Int J Alzheimers Dis (2011) 0.94
Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. J Immunol (2013) 0.93
β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS. Environ Toxicol Pharmacol (2013) 0.92
Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol Psychiatry (2012) 0.90
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. J Med Chem (2011) 0.90
Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J Med Chem (2011) 0.89
Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. ChemMedChem (2009) 0.87
Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. BMC Public Health (2011) 0.86
Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology (2012) 0.85
Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS One (2011) 0.85
Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. ACS Chem Neurosci (2014) 0.85
Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging (2013) 0.85
A dual role for the dREAM/MMB complex in the regulation of differentiation-specific E2F/RB target genes. Mol Cell Biol (2012) 0.85
The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS (2007) 0.84
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem (2012) 0.84
The RCPCH care pathway for food allergy in children: an evidence and consensus based national approach. Arch Dis Child (2011) 0.83
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem (2011) 0.83
Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. Curr Top Med Chem (2013) 0.83
Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2. Breast Cancer Res Treat (2010) 0.82
PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. PLoS One (2011) 0.82
Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr (2004) 0.82
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. J Med Chem (2012) 0.82
Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles. Bioorg Med Chem (2005) 0.82
1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor. Bioorg Med Chem (2008) 0.81
Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem (2009) 0.81
A novel BRCA1 mutation in a Spanish patient with ovarian cancer. Breast Cancer Res Treat (2008) 0.80
cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opin Ther Pat (2014) 0.80
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem (2014) 0.80
CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem (2007) 0.80
Factors associated to duration of hepatitis a outbreaks: implications for control. PLoS One (2012) 0.80
A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. Breast Cancer Res Treat (2009) 0.79
Anti-trypanosomatid benzofuroxans and deoxygenated analogues: synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies. Eur J Med Chem (2009) 0.79
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. ACS Chem Neurosci (2012) 0.79
Differences in sentinel influenza confirmed incidence rates and clinical presentation of influenza virus: 2008-09 seasonal vs 2009-10 pandemic influenza. Hum Vaccin (2011) 0.79
Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. Angew Chem Int Ed Engl (2014) 0.78
Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. Parkinsonism Relat Disord (2013) 0.78
5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. Eur J Pharm Sci (2012) 0.78
From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease. Curr Med Chem (2015) 0.77
The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. J Neurochem (2012) 0.77
Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats. J Neurosci Res (2009) 0.77
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. J Med Chem (2014) 0.77
Analysis of BRCA1 and mtDNA haplotypes and mtDNA polymorphism in familial breast cancer. Mitochondrial DNA (2013) 0.76
Supercritical fluid extraction of grape seeds: extract chemical composition, antioxidant activity and inhibition of nitrite production in LPS-stimulated Raw 264.7 cells. Food Funct (2015) 0.76
Inhibition of hippocampal long-term potentiation by high-fat diets: is it related to an effect of palmitic acid involving glycogen synthase kinase-3? Neuroreport (2017) 0.76
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. Eur J Med Chem (2011) 0.75
A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report. Oncol Lett (2013) 0.75
A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation. Oncol Lett (2011) 0.75
Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor. J Med Chem (2006) 0.75
Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. Eur J Med Chem (2013) 0.75
Enantioselective LC/MS method for the determination of an antimalarial agent Fenozan B07 in dog plasma. Chirality (2006) 0.75
Glycogen synthase kinase-3. Int J Alzheimers Dis (2011) 0.75
Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activity. Bioorg Med Chem (2003) 0.75
AMPA glutamate receptors and neuropathic pain. Mini Rev Med Chem (2003) 0.75
Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. Mini Rev Med Chem (2002) 0.75
Benzothiadiazine dioxide human cytomegalovirus inhibitors: synthesis and antiviral evaluation of main heterocycle modified derivatives. Antivir Chem Chemother (2003) 0.75
Reactivity of aluminum cluster anions with ammonia: selective etching of Al11(-) and Al12(-). J Chem Phys (2009) 0.75
Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress. Eur J Med Chem (2012) 0.75
Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. Bioorg Med Chem Lett (2005) 0.75
Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. Curr Top Med Chem (2016) 0.75
Developing a competency-based Pan-European Accreditation Framework for Health Promotion. Health Educ Behav (2012) 0.75
Products of the addition of water molecules to Al3O3- clusters: structure, bonding, and electron binding energies in Al3O4H2-, Al3O5H4-, Al3O4H2, and Al3O5H4. J Chem Phys (2004) 0.75